ObsEva Announces Appointment of Annette Clancy as Chair of the Board of Directors
19. Mai 2022 01:05 ET
|
ObsEva SA
GENEVA, Switzerland May 19, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced the appointment...
ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2022 Annual General Meeting held on May 18, 2022
19. Mai 2022 01:00 ET
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – May 19, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and...
ObsEva Announces First Quarter 2022 Financial Results and Provides Corporate Update
17. Mai 2022 07:00 ET
|
ObsEva SA
-Linzagolix for uterine fibroids: Received confirmation of positive CHMP opinion for marketing authorization application; United States NDA PDUFA date in Q3:22- -Linzagolix for endometriosis:...
ObsEva Announces First Quarter 2022 Financial Results and Provides Corporate Update
17. Mai 2022 01:00 ET
|
ObsEva SA
-Linzagolix for uterine fibroids: Received confirmation of positive CHMP opinion for marketing authorization application; United States NDA PDUFA date in Q3:22- -Linzagolix for endometriosis:...
ObsEva to Present at the H.C. Wainwright Global Investment 2022 Conference
16. Mai 2022 07:00 ET
|
ObsEva SA
GENEVA, Switzerland May 16, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that Company...
ObsEva to Present at the H.C. Wainwright Global Investment 2022 Conference
16. Mai 2022 01:00 ET
|
ObsEva SA
GENEVA, Switzerland May 16, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that Company...
ObsEva to Host Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Business Update
12. Mai 2022 07:00 ET
|
ObsEva SA
GENEVA, Switzerland – May 12, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that it plans...
ObsEva to Host Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Business Update
12. Mai 2022 01:00 ET
|
ObsEva SA
GENEVA, Switzerland – May 12, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that it plans...
ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at the 2022 ACOG Annual Clinical and Scientific Meeting
09. Mai 2022 07:00 ET
|
ObsEva SA
-Additional data from the PRIMROSE Phase 3 studies of linzagolix featured in four posters. Oral presentation took place on May 8, 2022 at 9:15am PT/12:15pm ET- GENEVA, Switzerland May 9, 2022 –...
ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at the 2022 ACOG Annual Clinical and Scientific Meeting
09. Mai 2022 01:00 ET
|
ObsEva SA
-Additional data from the PRIMROSE Phase 3 studies of linzagolix featured in four posters. Oral presentation took place on May 8, 2022 at 9:15am PT/12:15pm ET- GENEVA, Switzerland May 9, 2022 –...